Repeated exposure to the acute effects of exercise may contribute to the fight against cancer. Exercise may play a role in inhibiting the growth of colon cancer cells. After an acute bout of HIIT there were specific increases in inflammation immediately after exercise, which are hypothesised to be involved in reducing the number of cancer cells.
Capsaicin has been shown to alter the expression of several genes involved in cancer cell survival, growth arrest, angiogenesis and metastasis. Recently, many research groups have found that capsaicin targets multiple signaling pathways, oncogenes and tumor-suppressor genes in various types of cancer models. Capsaicin has been shown to induce apoptosis in many different types of cancer cell lines while leaving normal cells unharmed.
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone.
Certain treatments, including radiation and some chemotherapeutic drugs, work by damaging the DNA of cancer cells, but they can also cause damage to DNA of normal cells, which can contribute to accelerated biological aging.
There is growing evidence that cancers can go backward or stop, and researchers are being forced to reassess their notions of what cancer is and how it develops.
The immune system can stop the growth of a cancerous tumor without actually killing it. The study's authors call the cancer-immune system stalemate equilibrium. During equilibrium, the immune system both decreases the cancer's drive to replicate and kills some of the cancerous cells, but not quickly enough to eliminate or shrink the tumor.
The body has evolved anti-cancer responses that direct and slow the evolution of life-threatening cancer cells by not killing off too many cells too quickly. Natural adaptive therapies would use a similar approach to keep tumor size stable, while slowing the evolution of resistance. This strategy may be especially useful to prolong lifespan and quality of life in patients after a cancer has metastasized.
This discovery is unfortunately of little economic interest to pharmaceutical groups. The molecule is indeed simple and non-patentable and cancer prevention studies require a follow-up over many years.